NOTE

🌱 created from: peripheral T cell lymphoma

echelon-2

• Design: Phase 3, multi-center, double-blind, double-dummy, randomized, placebo-controlled, active-comparator
• Number of patients: 452
• Patients characteristics: Adults with previously untreated CD30-positive peripheral T-cell lymphomas
• Agent: Brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone for A+CHP group; cyclophosphamide, doxorubicin, vincristine, prednisone for CHOP group
• Treatment line: First-line
• Trial Acronym or NCTId Number: NCT01777152

Parameter	Result
Median PFS (months)	48.2 (A+CHP)
	20.8 (CHOP)
Hazard Ratio	0.71
p-value	0.0110

• Highlight of toxicity: Similar incidence and severity of febrile neutropenia and peripheral neuropathy between groups.
• One-line summarise: Front-line treatment with A+CHP showed superior progression-free survival and overall survival compared to CHOP in CD30-positive peripheral T-cell lymphomas with a manageable safety profile.